L
Lorenz Trümper
Researcher at University of Göttingen
Publications - 276
Citations - 22696
Lorenz Trümper is an academic researcher from University of Göttingen. The author has contributed to research in topics: Lymphoma & Diffuse large B-cell lymphoma. The author has an hindex of 53, co-authored 260 publications receiving 19534 citations. Previous affiliations of Lorenz Trümper include Deutsche Forschungsgemeinschaft & University of Cologne.
Papers
More filters
Journal ArticleDOI
A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients.
Marita Ziepert,Stefano Lazzi,Raffaella Santi,Federica Vergoni,Massimo Granai,Virginia Mancini,Annette M. Staiger,Heike Horn,Markus Löffler,Viola Pöschel,Gerhald Held,Gerald Wulf,Lorenz Trümper,Norbert Schmitz,Andreas Rosenwald,Elena Sabattini,Kikkeri N. Naresh,Harald Stein,German Ott,Lorenzo Leoncini +19 more
TL;DR: A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients that are likely to be at high risk of developing cancer.
Journal ArticleDOI
MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma
Jennifer Hüllein,Mikolaj Slabicki,Maciej Rosolowski,Alexander Jethwa,Stefan Habringer,Katarzyna Tomska,Roma Kurilov,Junyan Lu,Sebastian Scheinost,Rabea Wagener,Rabea Wagener,Zhiqin Huang,Marina Lukas,Olena Yavorska,Hanne Helfrich,René Scholtysik,Kyle Bonneau,Donato Tedesco,Ralf Küppers,Wolfram Klapper,Christiane Pott,Stephan Stilgenbauer,Birgit Burkhardt,Markus W. Löffler,Lorenz Trümper,Michael Hummel,Benedikt Brors,Marc Zapatka,Reiner Siebert,Reiner Siebert,Markus Kreuz,Ulrich Keller,Ulrich Keller,Wolfgang Huber,Thorsten Zenz +34 more
TL;DR: Targeting MDM4 to alleviate degradation of p53 can be exploited therapeutically across Burkitt lymphoma and other cancers with wild-type p53 harboring 1q gain, the most frequent copy number alteration in cancer.
Journal ArticleDOI
Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens.
A A Oyekunle,A A Oyekunle,Evgenii Shumilov,Philippe Kostrewa,Andreas Burchert,Lorenz Trümper,Patrick Wuchter,Patrick Wuchter,Gerald Wulf,Ulrike Bacher,Nicolaus Kröger +10 more
TL;DR: This study suggests that although causing significant morbidity, chemotherapy-based mobilization of CD34+ stem cell mobilization fails to improve remission status and the value of incorporating additional chemotherapy for SCM is thus not evident.
Journal ArticleDOI
Critical evaluation of current molecular MRD strategies including NGS for the management of AML patients with multiple mutations
Evgenii Shumilov,Johanna Flach,Raphael Joncourt,Naomi Porret,Gertrud Wiedemann,Anne Angelillo-Scherrer,Lorenz Trümper,Martin Fiedler,Barbara Jeker,Ursula Amstutz,Thomas Pabst,Ulrike Bacher +11 more
TL;DR: Clinicians face uncertainty on how to proceed in patients with persisting mutation load by NGS, how to interpret divergent kinetics of various markers by N GS, and how to weigh the different sensitivities of NGS and qPCR.
Journal ArticleDOI
Novel IGH and MYC Translocation Partners in Diffuse Large B-Cell Lymphomas.
Claudia Otto,René Scholtysik,Roland Schmitz,Markus Kreuz,Claudia Becher,Michael Hummel,Andreas Rosenwald,Lorenz Trümper,Wolfram Klapper,Reiner Siebert,Ralf Küppers +10 more
TL;DR: Overall, this study suggests that chromosomal translocations in DLBCL are more heterogeneous than previously known.